Instruction for use: Blemaren

Dosage form: Granules for solution for oral administration, effervescent tablets

Active substance: Acidum citricum + Kalii hydrocarbonas + Natrii citras

ATX

G04BC Drugs for the treatment of nephrourolythiasis

Pharmacological groups

Means that prevent the formation and promote the dissolution of concrements

Means for the treatment of nephrolithiasis [Means that inhibit the formation and promote the dissolution of concrements in combinations]

Nosological classification (ICD-10)

E80.2 Other porphyria: Porphyria; Acute intermittent porphyria; Porphyria of the skin; Pyrroloporphyria; Acute porphyria; Swedish porphyria

N20.9 Urinary stones, unspecified: Renal colic with urolithiasis; Calcium oxalate stones in hyperuricosuria; Calcium oxalate stones; Neuropathy of the urolithiasis; Primary urinary acid nephropathy; Urine stones; Urine calcification; Oxalate-calcium kidney stones; Salt diathesis

N21.9 Stones in lower urinary tract, unspecified

R82.9 Other and unspecified abnormalities detected in urine: Candiduria; Crystalluria; Urikozuria; Lipiduria; Nitritrium

Composition

Effervescent Tablets 1 tab.

Active substances: Citric acid 1197 mg

Potassium hydrogen carbonate 967.5 mg

Sodium citrate 835.5 mg

Auxiliary substances: lactose monohydrate - 115 mg; Mannitol - 105 mg; Adipic acid 35 mg; Macrogol 6000 - 100 mg; Sodium saccharinate - 10 mg; Flavored lemon - 35 mg

Pharmachologic effect

Mode of action - Alkalinizing urine, nephrolitholytic.

Dosing and Administration

Inside, after eating, previously dissolved in 200 ml of liquid (tea, fruit juices or alkaline mineral water).

The daily dose is 2-6 tablets spike. The daily dose is evenly distributed throughout the day. The dose is considered correctly selected in the event that the pH during the day is within the range of 6.2-7 (for dissolution of uric acid stones); 7.5-8.5 (for cystine stones); 7,2-7,5 (for the treatment of porphyria); At least 7 (in the treatment of cytostatics). If the pH value of urine is lower than indicated, the dose should be increased, if higher - reduced. Duration of treatment - 4-6 months.

Efficiency monitoring (urine pH determination) is carried out 3 times a day, before taking each single dose, with the help of indicator paper. The resulting color on paper is compared for 2 minutes with a scale and enter the value obtained in the control calendar.

In the presence of cystine stones and the treatment of porphyria, a special indicator paper with a pH of 7.2 to 9.7 should be used to monitor the efficacy.

Release form

The tablets are effervescent. In the tuba plastic, ukuporennoy plastic cover with a desiccant, 20 pcs. 4 tubes together with indicator paper and a control calendar in a cardboard box.

Manufacturer

«Esparma GmbH». Bielefelder Strasse, 1, 39171 Zülzetal, Germany.

Produced by: Allfamed Farbil Artschneitmittel GmbH. Germany, Hildebrandstrasse, 12, 37081 Göttingen.

The claims of consumers should be sent to the address of the «Esparham GmbH» office in Russia: 115114, Moscow, st. Letnikovskaya, 16, of. 306.

Tel .: (499) 579-33-70; Fax: (499) 579-33-71.

E-mail: [email protected]

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Blemaren

At a temperature not exceeding 25 ° C. After opening, protect from moisture.

Keep out of the reach of children.

The shelf life of the drug Blemaren

4 years.

Do not use beyond the expiration date printed on the package.